Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

NCT02500121 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma
Bladder Cancer

Interventions

OTHER: Placebo
DRUG: Pembrolizumab

Sponsor

Matthew Galsky

Collaborators

[object Object]
[object Object]